2020ACS Chemical BiologyOpen access

Synthetic Fluorinated l -Fucose Analogs Inhibit Proliferation of Cancer Cells and Primary Endothelial Cells

Yuanwei Dai, Ruth Hartke, Chao Li, Qiang Yang, Jun O. Liu, Lai‐Xi Wang

Open full text 35 citations

Abstract

Fucosylation is one of the most prevalent modifications on N- and O-glycans of glycoproteins, and it plays an important role in various cellular processes and diseases. Small molecule inhibitors of fucosylation have shown promise as therapeutic agents for sickle cell disease, arthritis, and cancer. We describe here the design and synthesis of a panel of fluorinated l -fucose analogs bearing fluorine atoms at the C2 and/or C6 positions of l -fucose as metabolic fucosylation inhibitors. Preliminary study of their effects on cell proliferation revealed that the 6,6-difluoro- l -fucose ( 3 ) and 6,6,6-trifluoro- l -fucose ( 6 ) showed significant inhibitory activity against proliferation of human colon cancer cells and human umbilical vein endothelial cells. In contrast, the previously reported 2-deoxy-2-fluoro- l -fucose ( 1 ) had no apparent effects on proliferations of all the cell lines tested. To understand the mechanism of cell proliferation inhibition by the fluorinated l -fucose analogs, we performed chemoenzymatic synthesis of the corresponding GDP-fluorinated l -fucose analogs and tested their inhibitory activities against the mammalian α1,6-fucosyltransferase (FUT8). Interestingly, the corresponding GDP derivatives of 6,6-difluoro- l -fucose ( 3 ) and 6,6,6-trifluoro- l -fucose ( 6 ), which are the stronger proliferation inhibitors, showed much weaker inhibitory activity against FUT8 than that of the 2-deoxy-2-fluoro- l -fucose ( 1 ). These results suggest that FUT8 is not the major target of the 6-fluorinated fucose analogs ( 3 and 6 ). Instead, other factors, such as the key enzymes involved in the de novo GDP-fucose biosynthetic pathway and/or other fucosyltransferases involved in the biosynthesis of tumor-associated glyco-epitopes are most likely the targets of the fluorinated l -fucose analogs to achieve cell proliferation inhibition. To our knowledge, this is the first comparative study of various fluorinated l -fucose analogs for suppressing the proliferation of human cancer and primary endothelial cells required for angiogenesis.

Open-access reader

About this research paper

What this paper is about

Fucosylation is one of the most prevalent modifications on N- and O-glycans of glycoproteins, and it plays an important role in various cellular processes and diseases. Small molecule inhibitors of fucosylation have shown promise as therapeutic agents for sickle cell disease, arthritis, and cancer. We describe here the design and synthesis of a panel of fluorinated l -fucose analogs bearing fluorine atoms at the C2 and/or C6 positions of l -fucose as metabolic fucosylation inhibitors. Preliminary study of their effects on cell proliferation revealed that the 6,6-difluoro- l -fucose ( 3 ) and 6,6,6-trifluoro- l -fucose ( 6 ) showed significant inhibitory activity against proliferation of human colon cancer cells and human umbilical vein endothelial cells. In contrast, the previously reported 2-deoxy-2-fluoro- l -fucose ( 1 ) had no apparent effects on proliferations of all the cell lines tested. To understand the mechanism of cell proliferation inhibition by the fluorinated l -fucose analogs, we performed chemoenzymatic synthesis of the corresponding GDP-fluorinated l -fucose analogs and tested their inhibitory activities against the mammalian α1,6-fucosyltransferase (FUT8). Interestingly, the corresponding GDP derivatives of 6,6-difluoro- l -fucose ( 3 ) and 6,6,6-trifluoro- l -fucose ( 6 ), which are the stronger proliferation inhibitors, showed much weaker inhibitory activity against FUT8 than that of the 2-deoxy-2-fluoro- l -fucose ( 1 ). These results suggest that FUT8 is not the major target of the 6-fluorinated fucose analogs ( 3 and 6 ). Instead, other factors, such as the key enzymes involved in the de novo GDP-fucose biosynthetic pathway and/or other fucosyltransferases involved in the biosynthesis of tumor-associated glyco-epitopes are most likely the targets of the fluorinated l -fucose analogs to achieve cell proliferation inhibition. To our knowledge, this is the first comparative study of various fluorinated l -fucose analogs for suppressing the proliferation of human cancer and primary endothelial cells required for angiogenesis.

Why it matters

OpenAlex reports 35 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Fucosylation is one of the most prevalent modifications on N- and O-glycans of glycoproteins, and it plays an important role in various cellular processes and diseases. Small molecule inhibitors of fucosylation have shown promise as therapeutic agents for sickle cell disease, arthritis, and cancer. We describe here the design and synthesis of a panel of fluorinated l -fucose analogs bearing fluorine atoms at the C2 and/or C6 positions of l -fucose as metabolic fucosylation inhibitors. Preliminary study of their effects on cell proliferation revealed that the 6,6-difluoro- l -fucose ( 3 ) and 6,6,6-trifluoro- l -fucose ( 6 ) showed significant inhibitory activity against proliferation of human colon cancer cells and human umbilical vein endothelial cells. In contrast, the previously reported 2-deoxy-2-fluoro- l -fucose ( 1 ) had no apparent effects on proliferations of all the cell lines tested. To understand the mechanism of cell proliferation inhibition by the fluorinated l -fucose analogs, we performed chemoenzymatic synthesis of the corresponding GDP-fluorinated l -fucose analogs and tested their inhibitory activities against the mammalian α1,6-fucosyltransferase (FUT8). Interestingly, the corresponding GDP derivatives of 6,6-difluoro- l -fucose ( 3 ) and 6,6,6-trifluoro- l -fucose ( 6 ), which are the stronger proliferation inhibitors, showed much weaker inhibitory activity against FUT8 than that of the 2-deoxy-2-fluoro- l -fucose ( 1 ). These results suggest that FUT8 is not the major target of the 6-fluorinated fucose analogs ( 3 and 6 ). Instead, other factors, such as the key enzymes involved in the de novo GDP-fucose biosynthetic pathway and/or other fucosyltransferases involved in the biosynthesis of tumor-associated glyco-epitopes are most likely the targets of the fluorinated l -fucose analogs to achieve cell proliferation inhibition. To our knowledge, this is the first comparative study of various fluorinated l -fucose analogs for suppressing the proliferation of human cancer and primary endothelial cells required for angiogenesis.

Key concepts: Fucosylation, Fucose, Fucosyltransferase, Chemistry, Cell growth, Biochemistry, Cancer cell, Glycoprotein

Related papers

Back to paper searchBrowse research topicsOriginal source
Synthetic Fluorinated l -Fucose Analogs Inhibit Proliferation of Cancer Cells and Primary Endothelial Cells — Research Paper | ScholarLens